Compare stocks
Market: US
ZBHZimmer Biomet
Add stock
Ticker or company
Summary
Traffic light — 10 checks
| Check | ZBH4 ✓ 4 — 1 ✕ |
|---|---|
| P/E vs its history | 26,0 |
| P/E vs industry | 26,0 |
| Forward P/E | 10,5 |
| Revenue growth, YoY | +7,0% |
| EPS growth, YoY | −1,7% |
| Net margin | 9,0% |
| Net debt / EBITDA | 2,6 |
| Free cash flow | $1,64 bn |
| Share count over a year | −3,7% |
| Cash runway | n/anot needed |
Metrics
Best WorstNo mark — in between
| Metric · better | ZBHTTM | Industry medianTTM |
|---|---|---|
| P/E TTM ↓ | 26,0 | 25,1 |
| Forward P/E ↓ | 10,5 | 16,2 |
| PEG ↓ | 4,3 | 2,2 |
| P/S TTM ↓ | 2,3 | 2,2 |
| EV/EBITDA ↓ | 14,8 | 17,3 |
| P/FCF ↓ | 17,2 | 19,5 |
Price, %
- ZBHn/a
Returns
Best WorstNo mark — in between
| Period | ZBH |
|---|---|
| 1 year | n/a |
| 3 years | n/a |
| 5 years | n/a |
| All time | n/a |
“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.
Analysts and insiders
Best WorstNo mark — in between
| ZBH | |
|---|---|
| Share of “buy” | 32% |
| Beat the forecast | 3 of 4 |
| Average “surprise” | +3,2% |
| Insiders over 12 months | sales $1,58 m |
Details are on each stock page.